Abbott presented new clinical data at Heart Rhythm Society 2026 demonstrating positive outcomes from four trials on its pulsed field ablation (PFA) and conduction system pacing (CSP) technologies. The FlexPulse IDE study showed that the TactiFlex Duo Ablation Catheter effectively treats complex atrial fibrillation cases with high safety and efficacy. Additional data from the Volt PFA System confirmed its safety and efficiency for posterior wall ablation. Abbott also revealed promising early results for its investigational UltiSynq CSP implantable cardioverter-defibrillator lead and AVEIR CSP leadless pacemaker system, both designed to improve physiological heart pacing. These advancements highlight Abbott's expanding portfolio aimed at improving treatment for heart rhythm disorders.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
